ExodusPoint Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-62,989
| Closed | -$2.53M | – | 1552 |
|
|
2026
Q1 | $2.53M | Sell |
62,989
-108,167
| -63% | -$2.33M | 0.02% | 677 |
|
|
2025
Q4 | $4.3M | Sell |
171,156
-23,602
| -12% | -$554K | 0.03% | 533 |
|
|
2025
Q3 | $4.41M | Buy |
+194,758
| New | +$4.54M | 0.05% | 461 |
|
|
2025
Q2 | – | Sell |
-250,414
| Closed | -$5.48M | – | 1444 |
|
|
2025
Q1 | $5.48M | Buy |
+250,414
| New | +$6.92M | 0.05% | 386 |
|
|
2024
Q3 | – | Sell |
-73,133
| Closed | -$2.81M | – | 1600 |
|
|
2024
Q2 | $2.81M | Buy |
73,133
+33,013
| +82% | +$1.5M | 0.02% | 655 |
|
|
2024
Q1 | $2.36M | Buy |
+40,120
| New | +$2.56M | 0.02% | 637 |
|
|
2023
Q3 | – | Sell |
-33,187
| Closed | -$3.02M | – | 1675 |
|
|
2023
Q2 | $3.02M | Buy |
33,187
+10,119
| +44% | +$873K | 0.02% | 645 |
|
|
2023
Q1 | $1.52M | Buy |
23,068
+8,276
| +56% | +$478K | 0.01% | 995 |
|
|
2022
Q4 | $765K | Buy |
+14,792
| New | +$785K | 0.01% | 1039 |
|
|
2022
Q1 | – | Sell |
-13,939
| Closed | -$659K | – | 2167 |
|
|
2021
Q4 | $659K | Buy |
+13,939
| New | +$549K | 0.01% | 1265 |
|
|
2021
Q3 | – | Sell |
-10,000
| Closed | -$632K | – | 2080 |
|
|
2021
Q2 | $632K | Buy |
+10,000
| New | +$516K | 0.01% | 1235 |
|
|
2020
Q4 | – | Sell |
-15,456
| Closed | -$466K | – | 1936 |
|
|
2020
Q3 | $466K | Buy |
+15,456
| New | +$462K | 0.01% | 1057 |
|
Other funds holding APLS
ExodusPoint Capital Management's APLS Position: Q2 2026 in Review
ExodusPoint Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 62,989 shares — an estimated $2.53M sold.
ExodusPoint Capital Management first reported a position in APLS in Q3 2020 and held it in 12 quarters. The position peaked at $5.48M in Q1 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- ExodusPoint Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- ExodusPoint Capital Management sold 62,989 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.53M.
- ExodusPoint Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2020 and held it in 12 quarters.
- ExodusPoint Capital Management's Apellis Pharmaceuticals position peaked at $5.48M in Q1 2025.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.